Phase III trial of sorafenib for locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer meets primary endpoint

Source: BioSpace Area: News Bayer has announced that a phase III trial of sorafenib in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival. The data have not yet been released but the company plans to present the data at an upcoming medical meeting and it anticipates that these data will form the basis for regulatory submission of sorafenib in the treatment of RAI-refractory differentiated thyroid cancer.   The DECISION (stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine refractory thyrOid caNcer) trial was an international, multicentre, randomised, placebo-controlled study that recruited 417 patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer*, who had received no prior chemotherapy, tyrosine kinase inhibitors, monoclonal antibodies that target VEGF or ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news